↓ Skip to main content

Dove Medical Press

Article Metrics

Clinical usefulness of mepolizumab in severe eosinophilic asthma

Overview of attention for article published in Therapeutics and Clinical Risk Management, June 2016
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (85th percentile)
  • High Attention Score compared to outputs of the same age and source (96th percentile)

Mentioned by

news
1 news outlet
twitter
4 tweeters

Citations

dimensions_citation
15 Dimensions

Readers on

mendeley
34 Mendeley
Title
Clinical usefulness of mepolizumab in severe eosinophilic asthma
Published in
Therapeutics and Clinical Risk Management, June 2016
DOI 10.2147/tcrm.s86299
Pubmed ID
Authors

Francesco Menzella, Mirco Lusuardi, Gloria Montanari, Carla Galeone, Nicola Facciolongo, Luigi Zucchi

Abstract

Asthma is a chronic inflammatory disorder of the airways with variable clinical severity from very mild and occasional symptoms to recurrent critical exacerbations, at risk of fatal or near-fatal outcome, in a small percentage of patients. Within the different inflammatory cascades involved in asthma, eosinophils play a central role in the pathogenesis and largely influence disease severity. Interleukin-5 (IL-5) is the main cytokine controlling eosinophil activity and proliferation at the site of inflammation. Mepolizumab was the first biological humanized anti-IL-5 monoclonal antibody tested in randomized clinical trials on eosinophilic asthma and other eosinophilic diseases. On the basis of several positive clinical efficacy data, it has recently been approved by the US Food and Drug Administration for the treatment of severe eosinophilic asthma. Unfortunately, high costs are at present a critical issue. Future studies will probably help in the correct selection of a potential "responder phenotype", allowing the prescription of this promising therapy to appropriate patients and best define cost-effectiveness issues.

Twitter Demographics

The data shown below were collected from the profiles of 4 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 34 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
France 1 3%
Unknown 33 97%

Demographic breakdown

Readers by professional status Count As %
Researcher 6 18%
Other 6 18%
Student > Bachelor 4 12%
Student > Ph. D. Student 3 9%
Student > Master 2 6%
Other 5 15%
Unknown 8 24%
Readers by discipline Count As %
Medicine and Dentistry 17 50%
Pharmacology, Toxicology and Pharmaceutical Science 2 6%
Agricultural and Biological Sciences 2 6%
Immunology and Microbiology 1 3%
Physics and Astronomy 1 3%
Other 2 6%
Unknown 9 26%

Attention Score in Context

This research output has an Altmetric Attention Score of 11. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 July 2016.
All research outputs
#1,259,459
of 12,485,238 outputs
Outputs from Therapeutics and Clinical Risk Management
#52
of 922 outputs
Outputs of similar age
#37,954
of 265,783 outputs
Outputs of similar age from Therapeutics and Clinical Risk Management
#1
of 51 outputs
Altmetric has tracked 12,485,238 research outputs across all sources so far. Compared to these this one has done well and is in the 89th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 922 research outputs from this source. They receive a mean Attention Score of 4.1. This one has done particularly well, scoring higher than 94% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 265,783 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 85% of its contemporaries.
We're also able to compare this research output to 51 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 96% of its contemporaries.